Head-to-head · free
Rhythm Pharmaceuticals, Inc. vs Sight Sciences, Inc.
RYTM vs SGHT — return on capital, cash generation, margins and balance sheet side by side.
RYTM
4 / 9
measures where RYTM leads
SGHT
5 / 9
measures where SGHT leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | RYTM · FY2025 | SGHT · FY2025 |
|---|---|---|
| Revenue | $189.8M | $77.4M |
| Net income | (196.5M) | (38.4M) |
| Revenue growth (yearly, multi-year) | 56.5% | 12.1% |
| Free cash flow | (116.6M) | (29.9M) |
| Free cash flow margin | -61.5% | -38.7% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -251.1% | -50.7% |
| Gross margin | 89.7% | 86.2% |
| Operating margin | -101.2% | -48.0% |
| Net debt / EBITDA | 0.28x | 1.41x |
Figures are as reported by each company; latest fiscal year shown.
Where Rhythm Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $953000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Sight Sciences, Inc.'s cash went (FY2025)
- Capital spending
- $224000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free